Tricalcium phosphate and osteogenin: a bioactive onlay bone graft substitute.
Tricalcium phosphate and osteogenin: a bioactive onlay bone graft substitute.
复制标题
磷酸三钙和骨生成素：一种具有生物活性的嵌体骨移植替代品。
DOI：
--
复制
发表时间：
1995
影响因子：
3.6
通讯作者：
German Steiner
中科院分区：
文献类型：
--
作者：
A. Breitbart;D. Staffenberg;Charles H. M. Thorne;P. Glat;N. Cunningham;A. Reddi;John Ricci;German Steiner
自体骨移植的缺点促使人们寻找可靠的覆盖骨移植替代品。在兔颅骨模型中，对磷酸三钙（一种可吸收陶瓷）和骨生成素（一种骨诱导蛋白）的组合作为覆盖骨移植替代物进行了评估。将28个磷酸三钙植入物（直径15毫米×5毫米；孔径100-200微米）分为实验组和对照组，放置在14只成年新西兰白兔的额骨上。在实验动物中，每个植入物中添加了 185 微克的骨生成素。在对照动物中，植入物未经处理。每隔 1、3 和 6 个月收获植入物，并使用苏木精和曙红组织学、显微放射照相术和组织形态扫描电子显微镜反向散射图像分析进行评估。第 1 个月时，经成骨素处理的植入物和对照植入物中的骨向内生长和磷酸三钙吸收极少。 3 个月时，经骨生成素处理的植入物和对照植入物均显示骨向内生长略有增加（8.85% 对比 5.87%），并且磷酸三钙有所减少（32.86% 对比 37.08%）。然而，在第 6 个月时，与对照种植体相比，经骨生成素处理的种植体显示骨向内生长显着增加（22.33% 对比 6.96%；p = 0.000），并且磷酸三钙减少（27.25% 对比 37.80%；p = 0.004）。对照植入物中的骨大部分在 6 个月时编织，而骨生成素处理的植入物主要包含成熟的板层骨和分化良好的骨髓。所有植入物在每个研究时间间隔都保持其原始体积。磷酸三钙/成骨素复合物具有保持其体积并随着磷酸三钙吸收而被新骨替代的优点，可作为覆盖骨移植替代物应用于临床。
The disadvantages of autogenous bone grafts has prompted a search for a dependable onlay bone graft substitute. A combination of tricalcium phosphate, a resorbable ceramic, and osteogenin, an osteoinductive protein, was evaluated as an onlay bone graft substitute in a rabbit calvarial model. Twenty-eight tricalcium phosphate implants (15 mm diameter x 5 mm; pore size, 100-200 microns) were divided into experimental and control groups and placed on the frontal bone of 14 adult New Zealand White rabbits. In the experimental animals, 185 micrograms of osteogenin was added to each implant. In the control animals, the implants were placed untreated. Implants were harvested at intervals of 1, 3, and 6 months, and evaluated using hematoxylin and eosin histology, microradiography, and histomorphometric scanning electron microscope backscatter image analysis. At 1 month there was minimal bone ingrowth and little tricalcium phosphate resorption in both the osteogenin-treated and control implants. At 3 months, both the osteogenin-treated and control implants showed a modest increase in bone ingrowth (8.85 percent versus 5.87 percent) and decrease in tricalcium phosphate (32.86 percent versus 37.08 percent). At 6 months, however, the osteogenin-treated implants showed a statistically significant increase in bone ingrowth (22.33 percent versus 6.96 percent; p = 0.000) and decrease in tricalcium phosphate (27.25 percent versus 37.80 percent; p = 0.004) compared with the control implants. The bone within the control implants was mostly woven at 6 months, whereas the osteogenin-treated implants contained predominantly mature lamellar bone with well-differentiated marrow. All implants maintained their original volume at each time interval studied. The tricalcium phosphate/osteogenin composite, having the advantage of maintaining its volume and being replaced by new bone as the tricalcium phosphate resorbs, may be applicable clinically as an onlay bone graft substitute.